Activities of Garenoxacin (BMS-284756) and Other Agents against Anaerobic Clinical Isolates

ABSTRACT A total of 590 clinical isolates consisting of 33 species of both gram-positive and gram-negative anaerobes were collected from nine centers in the Chicago area in 1998-1999. The largest number of isolates (330 isolates, 56%) belonged to the Bacteroides group. Isolates were tested by agar dilution against garenoxacin (BMS-284756, T-3811 ME), trovafloxacin, moxifloxacin, clindamycin, imipenem, piperacillin-tazobactam, and cefoxitin. All but one species (2% of Bacteroides vulgatus isolates) were fully susceptible to piperacillin-tazobactam and imipenem. A number of species were resistant to clindamycin. Among the fluoroquinolones, garenoxacin and trovafloxacin had an MIC at which 90% of the isolates tested were inhibited of <4 μg/ml for all but two species (Fusobacterium mortiferum/varium and Peptostreptococcus anaerobius).

[1]  M. Bassetti,et al.  Antimicrobial Activities of BMS-284756 Compared with Those of Fluoroquinolones and β-Lactams against Gram-Positive Clinical Isolates , 2002, Antimicrobial Agents and Chemotherapy.

[2]  L. Valera,et al.  Activity of the novel des-fluoro(6) quinolone BMS-284756 against methicillin-susceptible and -resistant staphylococci. , 2001, The Journal of antimicrobial chemotherapy.

[3]  M. Hammerschlag,et al.  Efficacy and safety of gemifloxacin in the treatment of community-acquired pneumonia: a randomized, double-blind comparison with trovafloxacin. , 2001, The Journal of antimicrobial chemotherapy.

[4]  M. Pfaller,et al.  Comparative antimicrobial spectrum and activity of BMS284756 (T-3811, a desfluoroquinolone) tested against 656 Enterobacteriaceae, including preliminary in vitro susceptibility test comparisons and development. , 2001, International journal of antimicrobial agents.

[5]  P. Rhomberg,et al.  Activity of BMS284756 (T-3811) tested against anaerobic bacteria, Campylobacter jejuni, Helicobacter pylori and Legionella spp. , 2001, Diagnostic microbiology and infectious disease.

[6]  J. Rosenblatt,et al.  Multicenter Survey of the Changing In Vitro Antimicrobial Susceptibilities of Clinical Isolates of Bacteroides fragilis Group, Prevotella, Fusobacterium, Porphyromonas, and PeptostreptococcusSpecies , 2001, Antimicrobial Agents and Chemotherapy.

[7]  M. R. Jacobs,et al.  Comparative Antianaerobic Activity of BMS 284756 , 2001, Antimicrobial Agents and Chemotherapy.

[8]  A. Bryskier.  Anti-anaerobic activity of antibacterial agents , 2001, Expert opinion on investigational drugs.

[9]  L. Valera,et al.  Antibacterial Spectrum of a Novel Des-Fluoro(6) Quinolone, BMS-284756 , 2000, Antimicrobial Agents and Chemotherapy.

[10]  H. Giamarellou.  Anaerobic infection therapy. , 2000, International journal of antimicrobial agents.

[11]  D. Snydman,et al.  Antimicrobial resistance and clinical outcome of Bacteroides bacteremia: findings of a multicenter prospective observational trial. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  E. Urbán,et al.  Prevalence of the carbapenemase gene (cfiA) among clinical and normal flora isolates of Bacteroides species in Hungary. , 2000, Journal of Medical Microbiology.

[13]  T. Fosse,et al.  Prevalence of beta-lactamase-producing strains among 149 anaerobic gram-negative rods isolated from periodontal pockets. , 1999, Oral microbiology and immunology.

[14]  J. Vincelette,et al.  Trends in Antimicrobial Resistance among Clinical Isolates of the Bacteroides fragilis Group from 1992 to 1997 in Montreal, Canada , 1999, Antimicrobial Agents and Chemotherapy.

[15]  D. Snydman,et al.  Multicenter Study of In Vitro Susceptibility of theBacteroides fragilis Group, 1995 to 1996, with Comparison of Resistance Trends from 1990 to 1996 , 1999, Antimicrobial Agents and Chemotherapy.

[16]  J. Picazo,et al.  Activities of New Antimicrobial Agents (Trovafloxacin, Moxifloxacin, Sanfetrinem, and Quinupristin-Dalfopristin) againstBacteroides fragilis Group: Comparison with the Activities of 14 Other Agents , 1999, Antimicrobial Agents and Chemotherapy.

[17]  D. Greenwood,et al.  Prevalence and degree of expression of the carbapenemase gene (cfiA) among clinical isolates of Bacteroides fragilis in Nottingham, UK. , 1999, The Journal of antimicrobial chemotherapy.

[18]  L. Ednie,et al.  Activities of Gatifloxacin Compared to Those of Seven Other Agents against Anaerobic Organisms , 1998, Antimicrobial Agents and Chemotherapy.

[19]  S. Finegold,et al.  In vitro activities of trovafloxacin against 557 strains of anaerobic bacteria , 1996, Antimicrobial agents and chemotherapy.

[20]  P. Montravers,et al.  Emergence of antibiotic-resistant bacteria in cases of peritonitis after intraabdominal surgery affects the efficacy of empirical antimicrobial therapy. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  Aldridge Ke.  The occurrence, virulence, and antimicrobial resistance of anaerobes in polymicrobial infections , 1995 .

[22]  M. Jacobs,et al.  Activity of CP 99,219 compared with those of ciprofloxacin, grepafloxacin, metronidazole, cefoxitin, piperacillin, and piperacillin-tazobactam against 489 anaerobes , 1994, Antimicrobial Agents and Chemotherapy.

[23]  C. Nord,et al.  Antimicrobial resistance in human oral and intestinal anaerobic microfloras , 1993, Antimicrobial Agents and Chemotherapy.

[24]  D. Hecht,et al.  Variation in the susceptibility of Bacteroides fragilis group isolates from six Chicago hospitals. , 1993, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[25]  E. Bruck,et al.  National Committee for Clinical Laboratory Standards. , 1980, Pediatrics.

[26]  R. Wise,et al.  The in vitro activity of BMS-284756, a new des-fluorinated quinolone. , 2002, The Journal of antimicrobial chemotherapy.

[27]  L. Chalkley,et al.  Comparative Activity of Eighteen Antimicrobial Agents against Anaerobic Bacteria Isolated in South Africa , 1999, European Journal of Clinical Microbiology and Infectious Diseases.

[28]  K. Aldridge.  The occurrence, virulence, and antimicrobial resistance of anaerobes in polymicrobial infections. , 1995, American journal of surgery.